Guilhem Solé, Stéphane Mathis, Diane Friedman, Emmanuelle Salort-Campana, Céline Tard, Françoise Bouhour, Armelle Magot, Djillali Annane, Bernard Clair, Gwendal Le Masson, Antoine Soulages, Fanny Duval, Louis Carla, Marie-Hélène Violleau, Tiphaine Saulnier, Sandrine Segovia-Kueny, Léa Kern, Jean-Christophe Antoine, Guillemette Beaudonnet, Frédérique Audic, Laurent Kremer, Jean-Baptiste Chanson, Aleksandra Nadaj-Pakleza, Tanya Stojkovic, Pascal Cintas, Marco Spinazzi, Alexandra Foubert-Samier, Attarian. Neurology
Among 3,558 patients with MG registered in the French database for rare disorders, 34 (0.96%) had COVID-19. The mean age at COVID-19 onset was 55.0 ± 19.9 years (mean MG duration: 8.5 ± 8.5 years). By the end of the study period, 28 patients recovered from COVID-19, 1 remained affected, and 5 died. Only high Myasthenia Gravis Foundation of America (MGFA) class (≥IV) before COVID-19 was associated with severe COVID-19 (p = 0.004); factors that were not associated included sex, MG duration, and medium MGFA classes (≤IIIb). The type of MG treatment had no independent effect on COVID-19 severity.
This registry-based cohort study shows that COVID-19 had a limited effect on most patients, and immunosuppressive medications and corticosteroids used for MG management are not risk factors for poorer outcomes.
This is a retrospective analysis of impact of coronavirus disease 2019 in a French cohort of myasthenia gravis. The study did not find evidence that use of immunosuppressant and corticosteroid has adverse outcome.